"Prospective Studies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
| Descriptor ID |
D011446
|
| MeSH Number(s) |
E05.318.760.500.750.625 N05.715.360.775.175.250.630 N06.850.520.450.500.750.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prospective Studies".
Below are MeSH descriptors whose meaning is more specific than "Prospective Studies".
This graph shows the total number of publications written about "Prospective Studies" by people in this website by year, and whether "Prospective Studies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 31 | 31 |
| 1997 | 0 | 51 | 51 |
| 1998 | 0 | 47 | 47 |
| 1999 | 0 | 62 | 62 |
| 2000 | 0 | 66 | 66 |
| 2001 | 0 | 68 | 68 |
| 2002 | 0 | 68 | 68 |
| 2003 | 0 | 79 | 79 |
| 2004 | 0 | 85 | 85 |
| 2005 | 0 | 89 | 89 |
| 2006 | 0 | 80 | 80 |
| 2007 | 0 | 89 | 89 |
| 2008 | 0 | 97 | 97 |
| 2009 | 0 | 90 | 90 |
| 2010 | 0 | 105 | 105 |
| 2011 | 0 | 139 | 139 |
| 2012 | 0 | 138 | 138 |
| 2013 | 0 | 189 | 189 |
| 2014 | 0 | 198 | 198 |
| 2015 | 0 | 213 | 213 |
| 2016 | 0 | 253 | 253 |
| 2017 | 0 | 267 | 267 |
| 2018 | 0 | 253 | 253 |
| 2019 | 0 | 279 | 279 |
| 2020 | 0 | 282 | 282 |
| 2021 | 0 | 240 | 240 |
| 2022 | 0 | 236 | 236 |
| 2023 | 0 | 200 | 200 |
| 2024 | 0 | 219 | 219 |
| 2025 | 0 | 202 | 202 |
| 2026 | 0 | 122 | 122 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prospective Studies" by people in Profiles.
-
Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to ?-Lactam/?-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa. J Infect Dis. 2026 Oct 15; 234(4):e985-e995.
-
Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology. 2026 Oct 27; 107(8):e218508.
-
Investigating the effects of intrathecal baclofen and ventral-dorsal rhizotomy on dystonia in children with cerebral palsy (PREDICT-Dystonia): protocol for a prospective observational clinical trial. BMJ Open. 2026 Oct 06; 16(10):e123926.
-
Immune correlates of protection are exposure-dependent: evidence from the Dominican Republic. Nat Commun. 2026 Oct 02; 17(1).
-
Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG. Clin Cancer Res. 2026 Oct 01; 32(19):4307-4318.
-
Understanding the Immune Response Changes to Clinical Interventions for Epstein-Barr Virus Infection Prior to Lymphoma Development in Children After Organ Transplants (UNEARTH). Pediatr Transplant. 2026 Oct; 30(10):e70487.
-
The Childhood Liver Disease Research Network's prospective characterization of pediatric primary sclerosing cholangitis. Hepatol Commun. 2026 Oct 01; 10(10).
-
Bayesian personalized dose constraints in selecting patients with non-small cell lung cancer for cardiac risk-adaptive treatment. Radiother Oncol. 2026 Nov; 224:111775.
-
Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort. Am J Hematol. 2026 Nov; 101(11):2827-2835.
-
Metabolites Associated With Long-Term Risk of Peripheral Artery Disease: The ARIC Study. Arterioscler Thromb Vasc Biol. 2026 Oct; 46(10):e324549.